Skip to content

Prolongation of oral antibiotic for prevention of periprosthesis joint infection after aseptic revision: a single center, prospective, randomized controlled trial

Prolongation of oral antibiotic for prevention of periprosthesis joint infection after aseptic revision: a single center, prospective, randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092755
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-12-09
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of periprosthesis joint infection after aseptic revision

Interventions

Control group (standard prevention):1.Preoperatively: prophylactic intravenous 1.5g of cefuroxime sodium was given within 1 hour prior to surgical skin incision. 2.Postoperative: Prophylactic intraven
Test group (extended oral prophylaxis):1.Preoperatively: prophylactic intravenous 1.5g of cefuroxime sodium was given within 1 hour prior to surgical skin incision. 2.Postoperative: Prophylactic intra

Sponsors

First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Undergoing revision surgery for artificial joints due to aseptic failure; (2) between the ages of 18 and 90 (inclusive), regardless of gender; (3) The subject agrees and signs an informed consent form approved by the Ethics Committee prior to any research procedure; (4) The subject is willing and able to participate in the prescribed follow-up visit and is able to complete the study activities.

Exclusion criteria

Exclusion criteria: (1) The diagnostic criteria for periprosthesis joint infection after arthroplasty in 2018 International consensus meeting; (2) The subject has a clear history of allergy to fluoroquinolones, cephalosporins; (3) Pregnant, parturient and lactating women; (4) Combined with bone tumors or other malignant tumors; (5) the subject is unable to tolerate the operation due to other medical conditions; (6) the subject is participating in other clinical trials; (7) The investigator believes that the subject has other diseases or conditions that are not suitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Incidence of infection;

Secondary

MeasureTime frame
HSS;Harris score;SF-12;VAS;Time interval between infections;Reoperation rate;CRP;ESR;

Countries

China

Contacts

Public ContactLi Cao

The First Affiliated Hospital of Xinjiang Medical University

xjbone@sina.com+86 139 0991 5960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026